Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -42.48% | 26.34% | 10.32% | 43.83% | -79.34% |
| Gross Profit | 42.48% | -26.34% | -10.32% | -43.83% | 79.34% |
| SG&A Expenses | -22.68% | 15.85% | -12.38% | -7.23% | -3.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.07% | 22.15% | 0.99% | 20.89% | 67.93% |
| Operating Income | 44.07% | -22.15% | -0.99% | -20.89% | -67.93% |
| Income Before Tax | 45.87% | 14.16% | 6.06% | -44.20% | -78.45% |
| Income Tax Expenses | -12.12% | -35.53% | 2.26% | -3.19% | 17.26% |
| Earnings from Continuing Operations | 45.75% | 14.35% | 6.01% | -43.78% | -78.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.75% | 14.35% | 6.01% | -43.78% | -78.11% |
| EBIT | 44.07% | -22.15% | -0.99% | -20.89% | -67.93% |
| EBITDA | 44.14% | -22.23% | -0.99% | -20.96% | -68.10% |
| EPS Basic | 46.55% | 15.40% | 7.15% | -42.35% | -76.88% |
| Normalized Basic EPS | 46.67% | -38.24% | -6.96% | -29.53% | -77.24% |
| EPS Diluted | 46.55% | 15.40% | 7.15% | -42.35% | -76.88% |
| Normalized Diluted EPS | 46.67% | -38.24% | -6.96% | -29.53% | -77.24% |
| Average Basic Shares Outstanding | 1.48% | 1.23% | 1.23% | 1.02% | 0.70% |
| Average Diluted Shares Outstanding | 1.48% | 1.23% | 1.23% | 1.02% | 0.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |